Trial Information

The hypothesis of this study is beneficial T cell reactivity in oral squamous cell carcinoma
(OSCC) tumors can be synergistically stimulated by blocking suppressor endothelial cells and
their induction of other inhibitory cell populations while also maturing immune inhibitory
CD34+ cells into antigen-presenting dendritic cells.

To test this hypothesis, newly diagnosed OSCC patients will be administered the COX 2
inhibitor celecoxib and/or 1,25(OH)2D3 for the 3 week duration between cancer diagnosis and
surgical treatment. The following aims will test the immunological and clinical
effectiveness of the combination treatment:

- 1. To block the suppressive activity of endothelial cells and increase the levels of
dendritic that are stimulatory to T cell reactivity, thereby synergistically increasing
intratumoral T cell reactivity. These functional immune analyses will use OSCC tissues
removed from untreated patients or patients treated with celecoxib and/or 1,25(OH)2D3.

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.